Whigham K A, Howie P W, Mack A, Prentice C R
Br J Obstet Gynaecol. 1979 Oct;86(10):806-9. doi: 10.1111/j.1471-0528.1979.tb10697.x.
In 26 women receiving either medroxyprogesterone acetate (Depo-Provera) injections or combined oestrogen-progestogen pills for contraception, tests of coagulation and fibrinolysis were performed before treatment, and after 8, 16 and 24 weeks of therapy. In the medroxyprogesterone group no significant changes were induced in fibrinogen, the vitamin K-dependent factors, or antithrombin III. Plasminogen levels fell during therapy, and were significantly lower than pre-treatment values after 16 and 24 weeks. By contrast, the 13 women receiving oral contraceptives showed raised levels of fibrinogen and plasminogen after 8 weeks of treatment, and of factors VII and X after 24 weeks. These data suggest that medroxyprogesterone acetate injections induce fewer changes in the blood coagulation system than oral contraceptives.
对26名接受醋酸甲羟孕酮(长效避孕针)注射或复方雌激素 - 孕激素 pill(此处可能有误,推测为复方雌激素 - 孕激素片)避孕的女性,在治疗前以及治疗8周、16周和24周后进行了凝血和纤维蛋白溶解测试。在醋酸甲羟孕酮组中,纤维蛋白原、维生素K依赖因子或抗凝血酶III没有显著变化。治疗期间纤溶酶原水平下降,在16周和24周后显著低于治疗前值。相比之下,13名接受口服避孕药的女性在治疗8周后纤维蛋白原和纤溶酶原水平升高,在24周后因子VII和X水平升高。这些数据表明,与口服避孕药相比,醋酸甲羟孕酮注射对血液凝固系统的影响较小。